Journal: Oncotarget

Article Title: Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts

doi: 10.18632/oncotarget.11826

Figure Lengend Snippet: Wild-type MCF7 cells were grown in complete medium (E2+) or in E2-deprived DCC medium (E2-) for 3 days, serum-starved for the last 24 hours and pre-treated with the indicated concentrations of A. sunitinib, B. cabozantinib, or C. NVP-BBT594 for 90 minutes before 30 minutes GDNF (20 ng/ml) stimulation. Total cell lysates were subjected to western blotting using the indicated antibodies. Tubulin was used as a loading control. Molecular size markers are in kDa.

Article Snippet: Cabozantinib and sunitinib were purchased from Tocris Bioscience.

Techniques: Western Blot, Control

Journal: Cancers

Article Title: Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer

doi: 10.3390/cancers12051189

Figure Lengend Snippet: Characterization of liposomes: hydrodynamic diameter histograms of empty (L) or liposomes containing paclitaxel (P-L), erlotinib (E-L), XL-184 (X-L), gemcitabine (G-L) and combination of gemcitabine plus paclitaxel (GP-L), gemcitabine plus erlotinib (GE-L), and gemcitabine plus XL-184 (GX-L) liposomes obtained from dynamic light scattering (DLS) intensity measurements. All the measurements were performed in deionized water at 25 °C.

Article Snippet: Gemcitabine, paclitaxel, XL-184, and erlotinib were procured from LC Laboratories, Woburn, MA, USA.

Techniques:

Journal: Cancers

Article Title: Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer

doi: 10.3390/cancers12051189

Figure Lengend Snippet: In vitro cellular cytotoxicities of drug-loaded liposomes in pancreatic cancer cell lines. AsPC-1 (upper panel) and PANC-1 (lower panel) cells were treated with various drug-loaded TTP-conjugated liposomes for 72 h. Then, cell viability was determined with cell titer glow assay. Dual drug-loaded liposomes showed a higher reduction in cell viability compared to single drug-loaded liposomes of each combination in all cell lines. Each data point represents the quadruplet results obtained from a single experiment. Abbreviations: L-liposome only; P-L represents liposomal paclitaxel; E-L represents liposomal erlotinib, X-L represents liposomal XL-184; G-L represents liposomal gemcitabine; GP-L represents liposome loaded with both gemcitabine and paclitaxel; GE-L represents liposome loaded with both gemcitabine and erlotinib, GX-L represents liposome loaded with both gemcitabine and XL-184.

Article Snippet: Gemcitabine, paclitaxel, XL-184, and erlotinib were procured from LC Laboratories, Woburn, MA, USA.

Techniques: In Vitro

Journal: Cancers

Article Title: Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer

doi: 10.3390/cancers12051189

Figure Lengend Snippet: In vivo therapeutic efficacy of drug-loaded liposomes in an orthotopic pancreatic tumor model. Briefly, 1 × 10 6 AsPC-1 cells were orthotopically injected into the head of the pancreases of 6–8 weeks old female mice. After 10 days of cells implantation, mice were imaged by using IVIS and randomized into five groups ( n = 5 in each group). Then, mice were treated with indicated groups 2×/week for 3 weeks. ( A ) The graphical representation of in vivo experimental plan. After the end of the treatment, mice were sacrificed, and endpoint tumor volume ( B ) and tumor weight ( C ) were measured. *** denotes p < 0.001 compared to control; ** denotes p < 0.01 compared to G-L group; and * denotes p < 0.05 compared to G-L group. (Abbreviations: G-L represents liposomal gemcitabine; GP-L represents liposome loaded with both gemcitabine and paclitaxel; GE-L represents liposome loaded with both gemcitabine and erlotinib, GX-L represents liposome loaded with both gemcitabine and XL-184).

Article Snippet: Gemcitabine, paclitaxel, XL-184, and erlotinib were procured from LC Laboratories, Woburn, MA, USA.

Techniques: In Vivo, Injection

Journal: Cancers

Article Title: Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer

doi: 10.3390/cancers12051189

Figure Lengend Snippet: In vivo survival improvement of dual drug-loaded liposomes in an orthotopic pancreatic tumor model. After 10 days of cell implantation, mice were imaged by using IVIS and randomized into five groups ( n = 5 in each group). Then, mice were treated with indicated groups 2×/week for 3 weeks. After the end of the treatment, mice were observed, and IACUC endpoints in the AsPC-1 tumor model for survival analysis were noted. ( A ) Represents the experimental plan of survival study and ( B ) represents median survival study graph developed using GraphPad software. ( C ) Improved survival days with indicated treatment groups along with statistical significance with respect to the vehicle or G-L Kaplan–Meier survival plots for both EGFR ( D ) and MET ( E ) were obtained from the analysis of the Kaplan–Meier-plotter [Pan-cancer RNA-seq] database. *** denotes p < 0.001 compared to control. (Abbreviations: G-L represents liposomal gemcitabine; GP-L represents liposome loaded with both gemcitabine and paclitaxel; GE-L represents liposome loaded with both gemcitabine and erlotinib, GX-L represents liposome loaded with both gemcitabine and XL-184).

Article Snippet: Gemcitabine, paclitaxel, XL-184, and erlotinib were procured from LC Laboratories, Woburn, MA, USA.

Techniques: In Vivo, Software, RNA Sequencing Assay